INHIBIKASE THERAPEUTICS, INC. (IKT) Free cash flow 2021–2025
INHIBIKASE THERAPEUTICS, INC. (IKT) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$27.8MFY2025 · since FY2021: -$14.3M → -$27.8M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$27.8M | -45.2% |
| FY2024 | -$19.1M | -5.8% |
| FY2023 | -$18.1M | -2.9% |
| FY2022 | -$17.6M | -23.1% |
| FY2021 | -$14.3M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice